Skip to main content
. 2022 Aug 5;13:929091. doi: 10.3389/fendo.2022.929091

Figure 1.

Figure 1

Summary of the most relevant information about biomarkers and immunotherapy efficacy in clinical trials in thyroid neoplasms. TAM, tumor-associated macrophage; MDSC, myeloid-derived suppressor cell; PD-L1T, PD-L1 membranous expression in tumor cells; TMB, tumor mutational burden; ORR, overall response rate; Mono-IO, immunotherapy monotherapy; IO-Combo, immunotherapy in combination with immunotherapy; MKI + IO, multikinase inhibitor in combination with immunotherapy.